Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totalling 816,800 shares, an increase of 830.3% from the September 15th total of 87,800 shares. Based on an average daily trading volume, of 2,820,000 shares, the short-interest ratio is currently 0.3 days.

SNOA stock opened at $5.86 on Thursday. The company has a market cap of $12.26 million, a P/E ratio of -2.31 and a beta of 0.77. The company’s 50-day moving average price is $5.76 and its 200 day moving average price is $6.91. Sonoma Pharmaceuticals has a 52 week low of $5.15 and a 52 week high of $15.19.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its earnings results on Monday, August 16th. The company reported ($0.52) earnings per share (EPS) for the quarter. The business had revenue of $3.68 million for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 59.12% and a negative net margin of 31.96%.

A number of hedge funds have recently modified their holdings of SNOA. Renaissance Technologies LLC increased its position in Sonoma Pharmaceuticals by 7.7% during the first quarter. Renaissance Technologies LLC now owns 98,826 shares of the company’s stock worth $734,000 after purchasing an additional 7,092 shares during the last quarter. Vanguard Group Inc. increased its position in Sonoma Pharmaceuticals by 44.9% during the second quarter. Vanguard Group Inc. now owns 27,975 shares of the company’s stock worth $205,000 after purchasing an additional 8,666 shares during the last quarter. Finally, Geode Capital Management LLC acquired a new position in Sonoma Pharmaceuticals during the second quarter worth approximately $221,000. 10.11% of the stock is owned by hedge funds and other institutional investors.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. Its products educe infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner.

See Also: What is the outlook for the FAANG stocks?

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with's FREE daily email newsletter.